Top Suppliers:I want be here



868540-17-4

868540-17-4 structure
868540-17-4 structure
  • Name: Carfilzomib
  • Chemical Name: carfilzomib
  • CAS Number: 868540-17-4
  • Molecular Formula: C40H57N5O7
  • Molecular Weight: 719.910
  • Catalog: Biochemical Inhibitor Proteases Proteasome inhibitor
  • Create Date: 2018-05-17 08:00:00
  • Modify Date: 2026-07-02 07:12:43
  • Carfilzomib is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.

Name carfilzomib
Synonyms Cfilzomib Impurity 94 Chloride
L-Phenylalaninamide, (αS)-α-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]
PR171
Cfilzomib (2R,4R)-Diol (7R)-Isomer
Cfilzomib Impurity 93
Cfilzomib Impurity 94
CfilzoMib salt
Cfilzomib Impurity 96
PR171;PR
Cfilzomib Impurity 99
Cfilzomib
Cfilzomib(For R & D only)
(2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
Cfezomil
Cfilzomib (alphaS)-alpha-[(4-Morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-phenylalaninamide
Cfilzomib (2S,4R)-Diol (7R)-Isomer
Cfilzomib Impurity
Cfilzomib irreversible proteasome inhibitor
PR-171
Cfilzomib (2R,4S)-Diol (7R)-Isomer
N-{(2S)-2-[(Morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-Methyl-1-[(2R)-2-Methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninaMide
(alphaS)-alpha-[(4-Morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-phenylalaninamide Cfilzomib(PR171)
PX-171-007
Caffezomib
Kyprolis
Cfilzomib (2S,4S)-Diol (7R)-Isomer
Cfilzomib, >=
(S)-4-Methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo
7(R)-i Cfilzomib (2S,4R)-diolQ: What is 7(R)-i Cfilzomib (2S,4R)-diol Q: What is the CAS Number of 7(R)-i Cfilzomib (2S,4R)-diol
(S)-4-Methyl-N-((S)-1-((S)-4-Methyl-1-((R)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylaMino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-MorpholinoacetaMido)-4-phenylbutanaMido)pentanaMide
Cfilzomib Impurity 59 Monomer
UNII-72X6E3J5AR
Cfilzomib API and intermediates
(S)-4-Methyl-N-[(S)-1-[[(S)-4-methyl-1-[(R)-2-methyloxiran-2-yl]-1-oxo-2-pentyl]amino]-1-oxo-3-phenyl-2-propyl]-2-[(S)-2-(2-morpholinoacetamido)-4-phenylbutanamido]pentanamide
Kafezomi
PR-171 (CfilzoMib)
L-Phenylalaninamide, (αS)-α-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]- (Cfilzomib impurity)
Cfilzomib Impurity 93 Chloride
Carfilzomib (PR-171)
CfilzoMib, Free Base
Cfilzomib API
Cfilzomib, proteasome inhibitor
N-{(2S)-2-[(4-Morpholinylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyl-2-oxiranyl]-1-oxo-2-pentanyl}-L-phenylalaninamide
(αS)-α-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
Cfilzomib Impurity 86
Cfilzomib Impurity 87
Cfilzomib Impurity 88
Cfilzomib Impurity 89
(alphaS)-alpha-[(4-Morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-phenylalaninamide
Cfilzomib Impurity 90
7(R)-i Cfilzomib (2R,4S)-diolQ: What is 7(R)-i Cfilzomib (2R,4S)-diol Q: What is the CAS Number of 7(R)-i Cfilzomib (2R,4S)-diol
CfilzoMib/PR
Description Carfilzomib is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
Related Catalog
Target

IC50: 5 nM (Proteasome)

In Vitro Carfilzomib displays preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, with over 80% inhibition at doses of 10 nM and above and little or no effect on the PGPH and T-L activities at doses up to 100 nM. Carfilzomib decreases the viability of ANBL-6, RPMI 8226 cells, U266 and KAS-6/1 cells with an IC50 less than 5 nM. Carfilzomib overcome Dex resistance, in that MM1.R cells reveals an IC50 of 15.2 nM, less than the value of 29.3 nM for parental MM1.S cells[1]. Co-treatment with carfilzomib and HDACIs leads to synergistic induction of cell death in various mantle cell lymphoma lines and primary mantle cell lymphoma cells. Combined treatment with carfilzomib or ONX0912 with vorinostat in HF-4B and Granta cells sharply increases caspase activation, PARP cleavage, JNK activation, MnSOD2 induction, and DNA damage[2].
In Vivo Carfilzomib (2.0 mg/kg, i.v.) in conbination with 70 mg/kg vorinostat virtually abrogates tumor growth in Granta-luciferace cell xenograft flank model. Combined treatment results in a pronounced reduction in bioluminescence compared to animals treated with single agents or controls with minimal toxicity[2].
Cell Assay WST-1 is used to determine the effects of proteasome inhibitors on cell proliferation according to the manufacturer's protocol. The inhibition of proliferation is calculated in relation to parallel control cells that receive vehicle alone and tabulated in KaleidaGraph 3.0.1 or Excel 2000. A linear spline function is used to interpolate the median inhibitory concentration (IC50) using XLfit 4 software. The degree of resistance (DOR) is calculated using the formula: DOR=IC50(resistant cells)/IC50(sensitive cells).
Animal Admin Animal studies are performed utilizing Beige-nude-XID mice. 10×106 Granta514 cells are pelleted, washed twice with 1X PBS, injected subcutaneously into the right flank. Once the tumors are visible, 5 to 6 mice are treated with carfilzomib±vorinostat and progress of tumor growth or regression is monitored. Stock vorinostat and carfilzomib is dissolved in DMSO and 10% sulfobutylether betacyclodextrin in 10 mM citrate buffer pH respectively. They are stored in −80°C in small aliquots and diluted before injection.
References

[1]. Kuhn DJ, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110(9):3281-90.

[2]. Dasmahapatra G, et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2011 Sep;10(9):1686-97.

Density 1.2±0.1 g/cm3
Boiling Point 975.6±65.0 °C at 760 mmHg
Melting Point 204-208°C
Molecular Formula C40H57N5O7
Molecular Weight 719.910
Flash Point 543.8±34.3 °C
Exact Mass 719.425781
PSA 172.43000
LogP 6.71
Vapour Pressure 0.0±0.3 mmHg at 25°C
Index of Refraction 1.551
Storage condition -20°C
HS Code 2933790090
HS Code 2933790090
Summary 2933790090. other lactams. VAT:17.0%. Tax rebate rate:9.0%. . MFN tariff:9.0%. General tariff:20.0%
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.